Xofigo

Expanding the Role of Radium-223 (Xofigo)

One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. [...]

By Malecare|2017-10-19T10:46:04-04:00October 18th, 2016|Advanced Prostate Cancer, Bone Metastases, Clinical Trials, Drugs & Treatments, radiopharmaceuticals, Uncategorized, Xofigo|0 Comments

A Brief Update of the Current Landscape of Bone Targeted Therapies for Prostate Cancer

Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs. We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity [...]

By Malecare|2016-10-14T13:14:25-04:00October 14th, 2016|Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Bone Meta